
Figure 1A.

Therapeutic Study: Dose and schedule for anti-OX40 treatment alone or in a combination with vaccine



Day 10 after tumor implantation

Antibody: Anti-OX40 (clone OX86)
Vaccine: CTL epitope from HPV16 E7 antigen, PADRE Thelper epitope and QuilA adjuvant.
Schedules: Anti-OX40 Ab treatment starting at Day 4 or Day 10 (1st day of tumor appearance) after tumor implantation
Doses: Twice a week 0.5, 1, and 2.5 mg/kg, i.p.
Readout: Survival
Number of groups: 14 groups (next slide) with n=5 mice/group

Experiment repeated twice – total of **140 C57/Bl6 mice** were use (14 groups x 5 mice/group x 2 repeats)







Figure 1B

Therapeutic Study: Dose and schedule for anti-OX40 treatment alone or in a combination with vaccine







Data are from 2 combined experiments (total of 10 mice/group)

Figure 2A

Therapeutic Study: Dose and schedule for anti-OX40 treatment alone or in a combination with vaccine

Schedules: Anti-OX40 Ab treatment starting at Day 4 or Day 10 (1st day of tumor appearance) after tumor implantation
Doses: Twice a week 1, and 2.5 mg/kg, i.p.
Readout: Tumor growth
Number of groups: 6 groups with n=5 mice/group

First study – total of 30 C57/Bl6 mice were used
Second study with another 30 C57/Bl6 mice (**total of 60 mice**)





Figure 2B

Therapeutic Study: Dose for anti-OX40 treatment alone or in a combination with vaccine



Data (tumor growth of individual mice is presented)

Figure 3A

Immunology Study: Dose for anti-OX40 treatment alone or in a combination with vaccine

Doses: Twice a week 0.5, 1, and 2.5 mg/kg, i.p.
Readouts: Evaluation of antigen-specific immune response and tumor-infiltrating T cell profiles.
Number of groups: 8 groups with n=5 mice/group

First study – total of 40 C57/Bl6 mice were used
Second study with another 40 C57/Bl6 mice (**total of 80 mice**)




Figure 3B

Immunology Study: Dose for anti-OX40 treatment alone or in a combination with vaccine





Figure 3C

Immunology Study: Dose for anti-OX40 treatment alone or in a combination with vaccine

Tumor-infiltrating T cells



*p≤0.05

Gated within CD45+CD3+

Figure 4A

Dissecting immune mechanisms for anti-OX40 Ab-based treatment

Schedule: Anti-OX40 Ab treatment starting on Day 10 (1st day of tumor appearance) after tumor implantation
Doses: Twice a week 1, 1.75, and 2.5 mg/kg, i.p.
Readout: Evaluation of splenic and tumor-infiltrating T cell profiles
Number of groups: 4 groups with n=5 mice/group

First study – total of 20 C57/Bl6 mice were used
Second study with another 20 C57/Bl6 mice (**total of 40 mice**)







Figure 4B

Dissecting immune mechanisms for anti-OX40 Ab-based treatment

T cell profiling in spleen







***p≤0.001

Figure 4C

Dissecting immune mechanisms for anti-OX40 Ab-based treatment




Figure 5A

Evaluation of the therapeutic efficacy of Vaccine/anti-OX40/1-MT combination treatment

Schedule: Anti-OX40 Ab treatment starting on Day 10 (1st day of tumor appearance) after tumor implantation. 1-MT is added to drinking water from day 10 till the end of experiment.
Doses: Anti-OX40 – 1mg/kg, 1-MT – 2mg/ml in drinking water.
Readout: Tumor growth and survival
Number of groups: 8 groups with n=5 mice/group

First study – total of 40 C57/Bl6 mice were used
Second study with another 40 C57/Bl6 mice
Immunology study with same groups (40 C57/Bl6 mice) (**total of 120 mice**)







Figure 5B

Evaluation of the therapeutic efficacy of Vaccine/anti-OX40/1-MT combination treatment










Figure 5B continued

Evaluation of the therapeutic efficacy of Vaccine/anti-OX40/1-MT combination treatment




Figure 5C

Evaluation of the therapeutic efficacy of Vaccine/anti-OX40/1-MT combination treatment




Figure 5D

Evaluation of the therapeutic efficacy of Vaccine/anti-OX40/1-MT combination treatment

